A Pilot Study Exploring the Use of Breath Analysis to
Differentiate Healthy Cattle from Cattle Experimentally
Infected with Mycobacterium bovis by Ellis, Christine K. et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
USDA National Wildlife Research Center - Staff
Publications
U.S. Department of Agriculture: Animal and Plant
Health Inspection Service
2-24-2014
A Pilot Study Exploring the Use of Breath Analysis
to Differentiate Healthy Cattle from Cattle
Experimentally Infected with Mycobacterium bovis
Christine K. Ellis
Randal S. Stahl
USDA-APHIS-Wildlife Services, randal.s.stahl@aphis.usda.gov
Pauline Nol
W. Ray Waters
Mitchell V. Palmer
USDA-APHIS-Wildlife Services, Mitchell.Palmer@ars.usda.gov
See next page for additional authors
Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc
Part of the Life Sciences Commons
This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff Publications
by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Ellis, Christine K.; Stahl, Randal S.; Nol, Pauline; Waters, W. Ray; Palmer, Mitchell V.; Rhyan, Jack C.; VerCauteren, Kurt C.;
McCollum, Matthew; and Salman, M. D., "A Pilot Study Exploring the Use of Breath Analysis to Differentiate Healthy Cattle from
Cattle Experimentally Infected with Mycobacterium bovis" (2014). USDA National Wildlife Research Center - Staff Publications. 1424.
https://digitalcommons.unl.edu/icwdm_usdanwrc/1424
Authors
Christine K. Ellis, Randal S. Stahl, Pauline Nol, W. Ray Waters, Mitchell V. Palmer, Jack C. Rhyan, Kurt C.
VerCauteren, Matthew McCollum, and M. D. Salman
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/icwdm_usdanwrc/
1424
A Pilot Study Exploring the Use of Breath Analysis to
Differentiate Healthy Cattle from Cattle Experimentally
Infected with Mycobacterium bovis
Christine K. Ellis1,2, Randal S. Stahl3, Pauline Nol4, W. Ray Waters5, Mitchell V. Palmer5, Jack C. Rhyan4,
Kurt C. VerCauteren2, Matthew McCollum4, M. D. Salman1*
1Animal Population Health Institute, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, United States of America,
2United States Department of Agriculture, Animal Plant and Health Inspection Service, Wildlife Services, National Wildlife Research Center, Fort Collins, Colorado, United
States of America, 3United States Department of Agriculture, Animal Plant and Health Inspection Service, Wildlife Services, National Wildlife Research Center, Fort Collins,
Colorado, United States of America, 4United States Department of Agriculture, Animal Plant and Health Inspection Service, Veterinary Services, Wildlife Livestock Disease
Investigations Team, Fort Collins, Colorado, United States of America, 5United States Department of Agriculture, Agricultural Research Service, National Animal Disease
Center, Ames, Iowa, United States of America
Abstract
Bovine tuberculosis, caused by Mycobacterium bovis, is a zoonotic disease of international public health importance. Ante-
mortem surveillance is essential for control; however, current surveillance tests are hampered by limitations affecting ease
of use or quality of results. There is an emerging interest in human and veterinary medicine in diagnosing disease via
identification of volatile organic compounds produced by pathogens and host-pathogen interactions. The objective of this
pilot study was to explore application of existing human breath collection and analysis methodologies to cattle as a means
to identify M. bovis infection through detection of unique volatile organic compounds or changes in the volatile organic
compound profiles present in breath. Breath samples from 23 male Holstein calves (7 non-infected and 16 M. bovis-infected)
were collected onto commercially available sorbent cartridges using a mask system at 90 days post-inoculation with M.
bovis. Samples were analyzed using gas chromatography-mass spectrometry, and chromatographic data were analyzed
using standard analytical chemical and metabolomic analyses, principle components analysis, and a linear discriminant
algorithm. The findings provide proof of concept that breath-derived volatile organic compound analysis can be used to
differentiate between healthy and M. bovis-infected cattle.
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Introduction
Bovine tuberculosis (bTB) is caused by Mycobacterium bovis, a
zoonotic pathogen of importance to public health and interna-
tional trade [1,2]. Globally approximately 8.8 million incident
cases of human tuberculosis occurred in 2010 [3], and while M.
tuberculosis was responsible for the majority of those cases, an
unknown proportion were likely attributable to M. bovis [4,5].
Eradication programs and milk pasteurization have decreased the
incidence of bTB in developed countries [6]; however, in
developing countries, disease prevalence in cattle may approach
10–14% [7,8]. Presently, in the United States of America (USA),
ante-mortem surveillance tests for cattle include the caudal fold
skin test (CFT), the comparative cervical skin test (CCT), and the
interferon gamma assay (IFN-c, IGRA; Bovigam, Prionics Ag,
Schlieren-Zurich, Switzerland). While these tests have reasonable
sensitivities and specificities [1,6,9], all take 48–72 hours to
produce results, and require multiple animal handlings (CFT,
CCT) or specialized laboratory procedures (IFN-c). In addition,
performance of these tests can be compromised by factors affecting
the immune response or confounding test interpretation [10].
Other in vitro assays (i.e., serologic assays, lymphocyte proliferation
assay, polymerase chain reaction) have limitations associated with
their accuracy and execution relative to ante mortem surveillance
[6].
There is emerging interest in diagnosing disease via identifica-
tion of volatile organic compounds (VOCs) produced by
pathogens, host-pathogen interactions, and biochemical pathways.
Volatile organic compounds may be found in the blood, breath,
feces, sweat, skin, urine, and vaginal fluids of humans and animals
[11–13]. The suite of VOCs found in these samples is influenced
by host biological variables such as age, breed, gender, genetics,
metabolic function, and physiological status; environmental factors
including diet, climate, husbandry, and seasonal variation;
symbiotic and infectious microbe-host interactions; and patho-
physiological responses to infections, toxins, or endogenous
metabolic pathway perturbations [11,14]. Volatile organic com-
pound analysis has been used in human and veterinary medicine
to explore suites of VOCs associated with infectious diseases [14–
21], metabolic disorders and diseases [22–25], neoplasia
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[11,26,27], and organ transplant rejection [28]. Additionally,
analysis of VOCs may prove useful for investigating metabolic and
biosynthetic pathway processes associated with homeostasis and
pathophysiological responses to disease. In cattle VOC analysis
has been explored as a method for diagnosis of bovine respiratory
disease [20], brucellosis [14], bovine tuberculosis [29], Johne’s
disease [14,30], ketoacidosis [31,32], and normal rumen physiol-
ogy.
Studies searching for host-derived biomarkers of disease have
classically been conducted using biofluids, cells, or tissues. Such
biomarkers are likely present as well in expired air, since breath
contains hundreds of endogenous and exogenous VOCs [33,34].
To date, VOC analysis has been used to search for unique
biomarkers associated with M. bovis and M. tuberculosis in serum
samples [14,35,36], cell cultures [36–41], tissues [42], and breath
[18,29,36]. Most research has attempted to isolate unique VOC
biomarkers that would indicate presence of mycobacterial
infection, with little work done to investigate potential changes
within host VOC profiles that represent host-pathogen interac-
tions or host responses to disease presence. Development of a
highly sensitive and specific diagnostic tool capable of identifying
such changes in VOC profiles would be of value in that sample
collection would be non-invasive, easily repeatable, cost and labor
efficient, and could be used in a point-of-care or ‘‘cow-side’’
setting. In this paper, we present the results of a pilot study
exploring the concept of using VOC biomarkers in breath as a
means to differentiate between non-infected cattle and cattle
experimentally infected with M. bovis.
Materials and Methods
Ethics Statement
Strict biosafety level-3 (BSL-3) safety protocols were followed
during all challenge and animal handling procedures to protect
personnel from exposure to M. bovis. All animal work was reviewed
and approved by the Institutional Biosafety and Animal Care and
Use Committees (IACUC) of the United States Department of
Agriculture (USDA), Agricultural Research Service (ARS),
National Animal Disease Center (NADC), Ames, Iowa, USA;
and the USDA, Animal and Plant Health Inspection Service
(APHIS), National Wildlife Research Center (NWRC), Fort
Collins, Colorado, USA prior to initiation of studies.
Mycobacterium bovis challenge strains
Two strains of M. bovis were used for challenge inoculum: (1) M.
bovis strain 95-1315 (USDA, APHIS designation) originally
isolated from a white-tailed deer in Michigan, USA [43]; (2) M.
bovis strain 10-7428_CO_Dairy_10-A (M. bovis strain 10-7428;
USDA, APHIS designation) a recent isolate from Colorado, USA.
Strains were prepared using standard procedures in Middlebrook
7H9 liquid media (Becton Dickinson, Franklin Lakes, NJ) [44].
Animals and Mycobacterium bovis challenge
Male Holstein calves (n = 23, approximately 1 year of age) were
obtained from a M. bovis and M. avium paratuberculosis-free herd in
Wisconsin, USA, transported to NADC, and housed outdoors for
approximately 2 months prior to placement into a BSL-3
agricultural facility at NADC. Animals were randomized to three
treatment groups: non-infected controls (n = 7); animals receiving
104 colony forming units (cfu) M. bovis strain 95-1315 (n = 8);
animals receiving 104 cfu M. bovis strain 10-7428 (n = 8) by aerosol
as described by Palmer et al 2002 [45]. Each treatment group was
housed according to IACUC guidelines in separate biocontain-
ment rooms with no exchange of air, feed or water occurring
between rooms. All animals were housed under the same
environmental conditions, fed the same diet, and were allowed
to acclimate to the new environment for approximately 3 months
prior to initiation of M. bovis challenge studies.
Diagnostic Tests Performed
Blood was collected from all calves at 2 weeks pre-challenge and
at 2, 3, 4, 6, 8, and 12 weeks post-challenge for in vitro evaluation of
cellular immune responses (CMI) to mycobacterial antigens
including recombinant Early Secretory Antigenic Target -6kDa:
Culture Filtrate Protein 10 fusion protein (rESAT-6:CFP10),
overlapping (14 mer) peptide cocktail of ESAT-6:CFP10, M. bovis
purified protein derivative (PPD), and M. avium PPD using the
Bovigam assay [46]. Comparative cervical tuberculin (CCT) skin
tests were performed at 12 weeks post-challenge as specified for the
eradication of bovine tuberculosis in the United States [47]. All
animals were humanely euthanized approximately 3.5 months
after challenge by intravenous administration of sodium pento-
barbital and necropsied. Tissues collected for bacteriologic
isolation of M. bovis and histopathologic analysis included: parotid,
medial retropharyngeal, mediastinal, and tracheobronchial lymph
nodes; lung; and liver. Tissues were processed for isolation of M.
bovis, and gross and microscopic lesions present were staged I–IV
as previously described [45,48].
Collection of VOC samples
Breath sample collection was conducted 90 days post inocula-
tion (DPI) and took place over three days, with one day dedicated
to each treatment group (Day 1: control treatment group; Day 2:
M. bovis strain 95-1315; Day 3: M. bovis strain 10-7428). Sampling
commenced and concluded at the same time each day. Collection
intervals per calf were approximately consistent for every animal
in the study. A modified equine nebulization mask (Aeromask,
Trudell Medical International, London, Ontario, Canada) was
used for breath sample collection. Modifications included install-
ment of three one-way valves to which charcoal filters were affixed
to remove environmental VOCs from inspired air, installment of a
one-way valve to allow excess expired air to escape, modification
of the silicon gasket to allow proper fitting to the muzzle of the test
subjects, and placement of a port at the apex of the mask to allow
attachment of the breath sample kit. Breath sample kits consisted
of: a 5 cm section of Tygon tubing (3/8 inch OD, J inch ID)
(Thermo Fisher Scientific, Inc., Waltham, MA, USA), a 3-piece
bioaerosol cassette (SKC Inc., Eighty Four, PA, USA) containing a
37 mm 0.22 um PTFE filter (Tisch Scientific, North Bend, OH,
USA) and a 37 mm cellulose pad (SKC Inc. Eighty Four, PA,
USA); a 20 cm section of Tygon tubing; a Tenax sorbent cartridge
(SKC Inc. Eighty Four, PA, USA); and a 20 cm section of Tygon
tubing attached to a vacuum pump (AirChek XR5000, SKC Inc.,
Eighty Four, PA, USA). Each calf was restrained unhaltered in a
standard cattle stanchion. The mask was held over the animal’s
muzzle and breath samples were collected at a rate of 1 L/min for
2 minutes (min). For background control, room air samples were
collected three times during the duration of animal sampling each
day using the same apparatus without the mask attached.
Immediately post-collection, each Tenax cartridge was capped,
placed in a Whirl-Pack (Nasco, Fort Atkinson, WI, USA) and
stored at 280uC. Samples were transported on dry ice to NWRC,
and stored at 280uC until analysis.
Method Validation
To establish the working range of the gas chromatography/
mass spectrometry (GC/MS) analysis method, 50 mg Tenax
samples were spiked with 0.01 ml of a low (,5 mg/mL) or high
Use of Breath Analysis to Identify M. bovis
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(,250 mg/mL) alkane stock solution containing each of the
following alkanes: decane (C10); undecane (C11); dodecane
(C12); tridecane (C13); and tetradecane (C14). Samples were
allowed to equilibrate following vortexing, at room temperature
for 45 minutes. Samples were extracted in 0.5 mL hexane and
analyzed by GC/MS using the same method for the breath
samples to establish repeatability and limits of detection for the
method. Linearity for the method was established across the range
of 0.24–10.0 mg/mL for each of the alkanes. Spiked samples were
replicated at n = 5 and the process was repeated on three separate
occasions to allow for inter- and intra-day comparisons for method
performance. Method limits of detection for each of the alkanes
were calculated as a concentration that would produce a peak
height three times the base line noise, measured peak to peak,
based on the total ion current (TIC) chromatograms from the low
fortified samples. Inter-day recoveries were evaluated based on the
magnitude of the standard deviation as a percent of the target
concentration (+/220%), while intra-day recoveries were com-
pared using ANOVA at a= 0.05.
Sample Preparation for GC/MS Analysis and GC/MS
Conditions
One Tenax sorbent cartridge from each animal was used for
GC/MS analysis. A 50 mg sample of Tenax was extracted from
each cartridge, and mixed with 0.5 mL hexane solvent. Each
sample was sonicated for 10 minutes and the solvent then
decanted into a GC vial. Analysis was performed using an Agilent
6890 GC coupled with an Agilent 5973 MS. Five microliters of
sample solvent were injected into the GC in pulsed spitless mode.
The inlet port temperature was 235uC, and the pulse pressure was
206.8 kPa (30 psi) for 0.5 minutes. The carrier gas was helium
delivered with an average velocity of 59.0 cm/s. The column used
was a DB-5 ms 30 m6250 mm column with a film thickness of
0.25 mm (J&W Scientific, Agilent Technologies, Santa Clara, CA,
USA). Analytes were eluted from this column using a thermal
gradient starting at 30uC and ramping at a rate of 5uC/1.0 min to
a final temperature of 150uC. The total GC run time was
26.5 min. The temperature of the transfer line was 280uC. The
MS was operated in positive ion mode, performing a total ion scan
ranging from 10 to 550 m/z with a threshold of 150 m/z at a scan
rate of 20 Hz. The MS source was operated at 230uC with the
quad set to 150uC. Data were generated as raw Agilent.dat files.
Data Processing
Data were analyzed qualitatively to identify VOCs present in
the chromatograms, and quantitatively to determine if treatment
group effects could be detected based on the ion abundances in the
observed peaks. Chromatograms were baseline corrected using the
region from 23–25 min, allowing for greater feature distinction in
the chromatograms. Significant peak features in the chromato-
grams were identified using two different approaches. Initially
features were identified using the Agilent Enhanced Chemstation
MSD Data Analysis Tool software (Agilent Technologies, Santa
Clara, CA, USA) and tentative peak compound identification was
determined using the National Institute of Science and Technol-
ogy (NIST) W8N08 database (www.nist.gov). Peaks were identified
as significant if the total peak area exceeded 5000 across all ions in
the peak. Compounds identified in the chromatograms using this
approach were evaluated as possible metabolites using the Kyoto
Encyclopedia of Genes and Genomes Database (KEGG) (www.
genome.jp/kegg/) [49].
Chromatograms were also processed using XCMS Online
(www.xcmsonline.scripps.edu) [49,50] [51]. Briefly, this software
identifies single ion (m/z) features that are significantly different
across chromatograms grouped by treatment. Peaks identified in
the chromatograms are aligned by a mean retention time
calculated across all chromatograms evaluated in the data set.
Peak features with relative intensity variance between sample
groups are identified and a cross-sample peak-matching is
performed in the METLIN Metabolite Database, identifying
peaks that may represent metabolites [50,52]. The ions identified
in this analysis as significantly different across treatment groups
were then used in the chemometric analysis described below.
Statistical Analysis
Mass spectral data from the XCMS Online analyses were used
to construct two sets of principle components analysis (PCA) and
linear discriminant analysis (LDA) classification models using the
chemometrics statistical package in ‘‘R’’ [53]. Initial PCAs were
calculated using the data from the control and one M. bovis
treatment group. The individual ions were median centered and
scaled to a variance of 1.0 using the median absolute deviation.
Outliers were identified as exceeding regular observations by the
97.5% quantile of a standard normal distribution of either distance
value, and by visually plotting the score distance and the
orthogonal distance against the sample number. Identified outliers
were removed from subsequent analyses. Principle component
analysis scores from M. bovis treatment groups were compared to
the same control treatment group, and then used to parameterize
LDA classification models using 2, 3, or 4 PCA scores [51].
The LDA classification models were written as two class models;
classifying a sample as either a control or one of the M. bovis
strains. A training dataset was constructed by randomly distrib-
uting two-thirds of the data, and a classification dataset was
constructed from the remaining one-third of the data. The LDA
classification was performed for 100 iterations and the resulting
predicted classification of each test animal in a given iteration was
compared to the actual treatment group assignment. Misclassifi-
cation rates were calculated as a percentage of the total number of
test animals misclassified per iteration of the model.
We compared the ability of our LDA classification models to
correctly identify control vs. infected cattle to currently used
surveillance tests by calculating diagnostic sensitivity and specific-
ity using the PCA scores generated from the XCMS Online
analysis. The best LDA classification model was used for each
calculation (four PCA scores M. bovis strain 95-1315; three PCA
scores M. bovis strain 10-7428). For both M. bovis strains, the
numbers of true positive (M. bovis-infected) and true negative
(control) samples classified across 100 iterations of the classification
simulation were summed. Samples that were misclassified as falsely
positive (negative sample incorrectly classified as positive) or falsely
negative (positive sample incorrectly classified as negative) were
also summed. Diagnostic sensitivity was calculated as the total
number of true positives divided by the sum of the true positives
plus false negatives. Diagnostic specificity was calculated as the
sum of all true negative samples divided by sum of the true
negative plus false positive samples [54]. These values are reported
as percentages.
Results
Diagnostic Tests
Specific CMI responses of all calves prior to and during the
study are reported elsewhere [46]. Briefly, prior to initiation of the
study, in some calves, Bovigam assay results demonstrated
responses to M. avium PPD that exceeded respective responses to
M. bovis PPD indicating environmental exposure to ubiquitous
non-tuberculous Mycobacteria spp. (NTM). During the study, the
Use of Breath Analysis to Identify M. bovis
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CMI responses of all M. bovis-inoculated calves to mycobacterial
antigens were robust, with no significant differences noted between
animals infected with M. bovis strain 95-1315 vs. M. bovis strain 10-
7428. As early as three weeks post-challenge, CMI responses by all
M. bovis-inoculated calves exceeded the pre- and post-challenge
responses by the uninoculated controls. All calves inoculated with
M. bovis, regardless of strain, were classified as reactors based upon
standard interpretation of the CCT skin test 12 weeks after
challenge. Calves in the non-infected control group were classified
as negative on CCT skin test. During the study, no significant
differences in clinical disease severity were observed between
calves infected with M. bovis strain 95-1315 vs. M. bovis strain 10-
7428. The severity of disease present grossly and microscopically
was mild in both M. bovis-inoculated treatment groups. Similar
gross and microscopic lesions were observed in the mediastinal
and tracheobronchial lymph nodes and lungs of all M. bovis-
inoculated calves examined (M. V. Palmer, unpublished data). M. bovis
was isolated by culture from all calves inoculated with M. bovis
strain 95-1315 or M. bovis strain 10-7428. Mycobacterium bovis was
not isolated from the non-infected control group.
Method validation
Method validation recoveries of low and high target concen-
trations for the alkanes were as follows: decane 0.55, and 5.5 mg/
mL; undecane 0.52 and 5.2 mg/mL, dodecane 0.52 and 5.2 mg/
mL, and for both tridecane and tetradecane 0.53 and 5.3 mg/mL.
The retention times observed for each of the compounds were 8.9
minutes for decane; 12 minutes for undecane; 15.1 minutes for
dodecane; 18 minutes for tridecane; and 20.8 minutes for
tetradecane. The observed mean (mean +/21 standard deviation)
concentrations determined for each of the alkanes in the extracting
solutions across the three repetitions of the procedure are
presented in Table 1. All observed concentrations fell within
20% of the target. Standard deviations for the means fell within
10% of the mean. Limits of detection for each of the compounds
across three repetitions of the extraction procedure consistently fell
below 0.1 mg/mL. The concentrations of each of the alkanes
observed across the three intraday repetitions of the procedure at
the high and low fortification levels were not significantly different
at the a= 0.05 significance level.
Compound identification
The peaks identified by the Agilent analysis were quantified and
peak areas could be tentatively determined for 14 compounds
(Table 2) using the NIST W8NO8 mass spectral library. The
volatile compounds tentatively identified included acetals; alco-
hols; aldehydes; amines; hydrocarbons; ketones; an amino acid; a
piperidine compound; and a pyrrolidine compound. Five
compounds (4-hydroxy-4-methyl-2-pentanone, benzaldehyde, 1-
ethyl-2-pyrrolidinone, a, a - dimethyl-benzenemethanol, and
nonanal) were present in significantly greater concentration
(p,0.05) in the M. bovis-infected treatment groups.
Cloud Plots
The two aligned between-groups comparisons generated by
XCMS Online are presented as cloud plots (Figure 1 A and B)
[49,55]. XCMS Online identified 137 peak features in the M. bovis
strain 95-1315 vs. control group comparison, with 17 up-regulated
features of statistical significance (p,0.05, .1.5 fold intensity
change between treatment groups) present in the infected
treatment group chromatograms (Figure 1A). There were 171
peak features identified in the M. bovis strain 10-7428 vs. control
groups comparison with 51 features identified as significantly
different between groups (p,0.01, .1.5 fold intensity change
between treatment groups) (Figure 1B).
Principle Components Analysis
Principle components analysis plots were constructed using the
first two principle components scores based on all the features
identified in the XCMS Online analysis of the chromatograms.
The ability to distinguish between M. bovis-infected and control
group samples based on the spatial distribution of the treatment
group scores is illustrated in Figure 2A and B. In both comparisons
there is distinct clustering of treatment group samples and a well-
defined separation between the infected group and control group
Table 1. Solvent extraction method development mean alkane concentrations observed across replicates.
Replicate/Alkane (ppm) C10 (decane) C11 (undecane) C12 (dodecane) C13 (tridecane) C14 (tetradecane)
Day 1
Low Mean
High Mean
MLOD
0.52+0.01
5.70+0.33
0.056
0.48+0.00
5.55+0.35
0.068
0.49+0.02
5.67+0.37
0.079
0.50+0.01
5.82+0.38
0.067
0.48+0.01
5.89+0.44
0.068
Day 2
Low Mean
High Mean
MLOD
0.47+0.05
5.06+0.59
0.051
0.42+0.05
4.75+0.60
0.060
0.43+0.04
4.87+0.62
0.048
0.45 + 0.05
4.87 + 0.63
0.059
0.47+0.06
4.93+0.65
0.056
Day 3
Low Mean
High Mean
MLOD
0.53+0.05
5.70+0.33
0.070
0.50+0.06
5.55+0.35
0.093
0.51+0.05
5.67+0.37
0.087
0.51 + 0.05
5.82 + 0.38
0.075
0.51+0.05
5.89+0.44
0.092
ANOVA Results
Low Fortification
Comparison
Fcritical = 3.89
Df = 2,12
F = 0.78
P = 0.49
Df = 2,12
F = 1.99
P = 0.18
Df = 2,12
F = 3.24
P = 0.07
Df = 2,12
F = 1.22
P = 0.33
Df = 2,12
F = 0.004
P = 0.995
High
Fortification
Comparison
Df = 2,12
F = 1.36
P = 0.29
Df = 2,12
F = 2.38
P = 0.13
Df = 2,12
F = 1.88
P = 0.20
Df = 2,12
F = 3.00
P = 0.088
Df = 2,12
F = 2.42
P = 0.13
doi:10.1371/journal.pone.0089280.t001
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Figure 1. Cloud plots of aligned GC/MS chromatograms generated with XCMS Online. (A) Control vs. M. bovis strain 95-1315 analysis. (B)
Control vs. M. bovis strain 10-7428 analysis. Control treatment group chromatograms are depicted below the X-axis, and M. bovis-infected
chromatograms are positioned above. Up-regulated features of statistical significance are identified with green-colored circles located at the top of
the plot, and down-regulated features are identified by red-colored circles located at the bottom of the plot. The color intensity of each circle
represents the statistical significance of the feature difference, with brighter circles having lower p-values. The diameter of each circle represents a
log-fold increase or decrease in abundance (i.e., larger circles correspond to peaks with greater fold differences).
doi:10.1371/journal.pone.0089280.g001
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sample clusters, indicating that the VOC profiles of the M. bovis-
infected cattle are distinctly different from those of the control
cattle. It is interesting to note that while the chromatograms of M.
bovis strain 95-1315-infected cattle did not contain many
statistically significant peaks (n = 17; p,0.05, .1.5 fold intensity
change between treatment groups) (Figure 1A), the magnitude of
peaks present did allow for differentiation, particularly after
relaxing the 1.5 fold increase criteria and including ion fragments
that met only the p,0.05 criteria.
Linear Discriminant Analysis and Sensitivity and
Specificity
Linear discriminant analysis models based on ions identified by
XCMS Online as significantly different across treatment groups
(p,0.01, M. bovis strain 10-7428; p,0.05, M. bovis strain 95-1315)
did allow for classification (Table 3). The misclassification
probabilities (combined false positive and false negative) for the
control vs. M. bovis strain 10-7428 model were 11.25%, 8.75%,
and 12.00%; and the misclassification probabilities for the control
vs. M. bovis strain 95-1315 model were 22.09%, 17.50% and
2.25% (based on 2, 3, or 4 principle component scores,
respectively). Based on the LDA model classifications, the
Figure 2. Principle Components Analysis results. (A) Control vs. M. bovis strain 95-1315. (B) Control vs. M. bovis strain 10-7428.
doi:10.1371/journal.pone.0089280.g002
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sensitivity and specificity for the control vs. M. bovis strain 10-7428
and control vs. M. bovis strain 95-1315 were 83.8% and 96.4%
(based on the three score model) and 97.4% and 99.2% (based on
the 4 score model), respectively.
Discussion
In this pilot study we demonstrate that it is possible to
discriminate between healthy cattle and cattle experimentally
infected with M. bovis at 90 DPI, using GC/MS analysis of breath
samples. The analytical and statistical approaches we describe
provide a means of identifying compounds from breath analysis
that may be diagnostically significant in identifying the presence of
bovine tuberculosis infection. The cloud plots generated in the
XCMS Online analysis demonstrate it is possible to differentiate
between infected and healthy calves based on changes in ion
intensities associated with VOCs common across the treatment
groups. The results of our PCA further demonstrate this capability
based on the distinct clustering of within group samples and the
clear separation of between groups samples. The robustness of our
models is supported by the low misclassification rates present in
the LDA and by the calculated sensitivity and specificity values of
our classification models, as those values observed compare
favorably with the standard ante-mortem surveillance tests used
in the United States [6,9,56,57]. Our results were unexpected in
that the intent of our work was to identify unique VOCs in the
breath of M. bovis-infected cattle, based on the results of other
studies exploring VOC analysis as a means of diagnosing
tubercular disease in cattle [29] and other animal species
[42,58], with potential applications to humans [18,36,38,39,55].
However, our findings lead us to consider that the VOCs
identified in our study represent up- or down-regulation of
metabolic pathways, physiological or immune responses, or
homeostatic perturbations caused by M. bovis infection.
The calves in our study were procured from a herd in which
bovine tuberculosis- and M. avium paratuberculosis-infections were
not reported or observed, were held in a controlled environment
under observation for months prior to the start of and throughout
the duration of the study, and were screened for exposure to M.
bovis, M. avium, and M. avium paratuberculosis prior to challenge. In
some animals, responses to M. avium PPD did exceed respective
responses to M. bovis PPD prior to experimental infection with M.
bovis indicating environmental exposure to ubiquitous NTM [46].
In general, NTM are rapidly cleared by cattle; thus, it was not
anticipated that transient exposure and sensitization of the cattle to
NTM would result in significant interference with detection and
interpretation of M. bovis specific VOCs. The robust immune
responses, gross pathologic and histopathologic observations, and
bacteriological results in all M. bovis infected animals vs. controls
lead us to state with confidence that the changes noted in the VOC
profiles of the M. bovis-infected calves in our study were likely
caused by M. bovis infection. We cannot, however, state that the
changes noted in the breath VOC profiles are exclusive to M. bovis
infection. Our findings do demonstrate that it is possible to
differentiate between healthy and diseased calves, when M. bovis is
present as the infectious agent. These results illustrate the need for
further research exploring the breath VOC profiles of healthy
cattle and those experiencing disease caused by M. bovis and other
etiological agents in order to more thoroughly evaluate the
robustness of VOC analysis as a disease detection method. To
date, limited research has been conducted exploring the use of
VOC analysis as a means to differentiate between healthy cattle
and cattle infected with any etiological agent [19,20,29,31,32,59–
61]. This is likely due partly to the practical difficulties in adapting
human breath sampling and analysis strategies to cattle, and in
interpreting VOC profiles produced by animals that have a
microbial fermentation-driven digestive system.
Tenax is widely used to concentrate nonpolar VOCs in air
samples and is typically thermally desorbed before being analyzed
by GC/MS [62]. However, Tenax has also been solvent extracted
when used in air or aqueous phase sampling, particularly in
environmental applications where large molecular weight com-
pounds are being monitored [63–66]. The decision to use a solvent
extraction method in this study was driven by the possibility that
large organic molecules entrained in breath water vapor might be
retained on the Tenax and would not be thermally labile. This is
presently the subject of ongoing work.
We were able to provide tentative identification of 14
compounds using the Agilent Enhanced Chemstation MSD Data
Analysis Tool/NIST W8N08 (Table 1). Seven of the compounds
have been previously described in association with cattle
[19,29,31,32,67–71], or as potential biomarkers for M. bovis
[29,40] or M. tuberculosis [41,72] (Table 4). Tentative identification
and change in peak intensity of nonanal is interesting as this
compound is a lipid peroxidation by-product present in the breath
of healthy humans and detected in greater concentrations in the
breath of humans with respiratory tract disease [73,74]. Potential
metabolic pathway associations were identified for 6 compounds
(toluene; styrene; benzaldehyde; 2-ethyl-1-hexanol; a-acetophe-
none; 1, 1-dimethyl 2-(1-methylethyl) cyclopropane)(Table 4).
Review of the literature identified one other study exploring the
VOC profiles of cattle infected with M. bovis. In that study 16
Table 3. Misclassification rates for Least Discriminant Analysis (LDA) models based on Principle Components Analysis (PCA) scores
for XCMS Online data.
Number of PCA Scores Used in the Model bTB strain 95-1315 vs. Control bTB strain 10-7428 vs. Control
2 22.09% 11.25%
3 17.50% 8.75%
4 2.25% 12.00%
bTB (+) samples n = 7 n = 7
Control samples n = 8 n = 7
Number of variables 16 51
Training Data Set n = 10 n = 10
Classification Data Set n = 5 n = 4
doi:10.1371/journal.pone.0089280.t003
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VOCs were tentatively identified, with 10 VOCs present in the
breath of all the cattle sampled, four VOCs apparently exclusive to
healthy cattle, and two VOCs apparently exclusive to cattle
infected with M. bovis. Only two VOCs were consistent between
that study and our study. Acetophenone was found in the breath of
all cattle in both studies. Nonanal was present in the breath of all
cattle in our study, but was absent from the breath VOC profiles of
M. bovis-infected cattle and present only in a subset of healthy
cattle in the other study [29].
While it is conceivable that some VOCs produced by
monogastric animals, humans, cattle, and bacteria may be similar,
there is limited continuity in the suites of VOCs identified when
comparing studies performed on healthy cattle vs. cattle with BRD
or M. bovis infection, studies of healthy humans vs. humans with
Table 4. Comparison of compounds identified in cattle and humans.
Compound Cattle Humans Culture
Potential metabolic
pathway [78] Other [71,79]
1,1-Diethoxyethane Found in onions, grapes. Used as a
flavoring ingredient in fruit and
alcohols. Endogenous metabolite.
Food metabolite.
Toluene Ketosis [31,32] BRD
[19] M. bovis [29]
M. tuberculosis M. bovis
BCG Bos tarus
Found in allspice, lime oil and some
foods. Food metabolite. Toxin and
pollutant metabolite. Found in some
plants.
Diethylamine Healthy [70] Occurs naturally in some foods and
plants. Endogenous metabolite.
4-Hydroxy-4-methyl-2-
pentanone
M. tuberculosis [41] Also known as diacetone alcohol.
Found in fruits. Endogenous
metabolite. Food metabolite.
Styrene Healthy [67] Tuberculosis [72] M. tuberculosis M. bovis
BCG Bos tarus
Found naturally in some plants and
a variety of foods including fruits,
vegtables, nuts, beverages, meats
and dairy products. Exhibits signaling
and catabolic functions. Food
metabolite. Biofunctions include
catabolism and signaling.
Benzaldehyde M. tuberculosis M. bovis
BCG Bos tarus
Occasionally found as a volatile
compound in urine. Food additive.
By-product in phenylalanine
metabolism.
1-Ethenyl-2-pyrrolidinone Also known as polyvidone. Used as
a food additive. 2-pyrrolidinone is a
lactam cyclization product of
gamma-aminobutyric acid (GABA).
Food metabolite.
1-Methyl-3-piperidinone
2-Ethyl-1-hexanol Healthy [69] M. tuberculosis M. bovis
BCG Bos tarus
May occur naturally in some fruits
and grains, olive oil, tobacco, and
teas. Endogenous metabolite. Food
metabolite. Biofunctions include cell
signaling, energy source, and
membrane integrity.
a-Acetophenone Healthy [69] BRD
[19] M. bovis [29]
M. tuberculosis M. bovis
BCG Bos tarus
Found in some plants. Used as a
food flavoring ingredient. Additive
in cigarettes. Has anti-fungal
properties. Drug metabolite. Food
metabolite.
a,a-Dimethyl-
benzenemethanol
3-Heptanone Found naturally in spearmint. Used
as a flavoring ingredient. Endogenous
metabolite. Food metabolite.
Nonanal BRD [19] M. bovis
[29]
Tuberculosis [72] Asthma,
COPD [73,74]
M. tuberculosi M. bovis
BCG Bos tarus
Lipid peroxidation by-product
1-1-Dimethyl-
2-(1-methylethyl)
cyclopropane
Cyclopropane fatty acids are
produced by some microorganisms
and plants. American Oil Chemists
Society (AOCS) Lipid Library www.
lipidlibrary.aocs.org
doi:10.1371/journal.pone.0089280.t004
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tuberculosis, and between M. tuberculosis cultures grown in vitro in
different types of solid and liquid media [18–
20,29,31,32,41,59,61,67,68,72,75]. Volatile compounds identified
as biomarkers for specific pathogens in culture or preliminary
human or animal testing have been found in the breath of normal
subjects and subjects with diseases of different etiology, or
associated with specific foods or other materials [41,73,76]. Likely
explanations for these inconsistencies include individual variabil-
ity; similarities in host response to pathogen presence; pathobio-
logical similarities between pathogens; endogenous and exogenous
factors; and, relative to cattle, the dynamic nature of rumen gases.
Identifying endogenous and exogenous factors that may affect
VOC suite composition and concentrations of VOCs present in
breath is important. Endogenous VOCs are comprised of blood-
borne compounds produced by metabolic, hemostatic, or patho-
logic processes that passively diffuse across the blood-alveolar
interface or are produced within the respiratory tract. Exogenous
VOCs present in the environment that are passively inspired then
expired, or are present in food and water may be inadvertent
contaminants [76].
The diverse methods of VOC collection and analytical methods
that have been used are likely to have contributed to the variability
in results as well. For example, methods of sample collection have
included Tedlar bags, Tenax sorbent cartridges, and SPME fibers
of various types [19,20,29,35,60,61,67,75], and sample analysis
methods have included, but have not been limited to, thermal
desorption-GC/MS [19,61,67], proton-transfer-reaction mass
spectrometry (PTR-MS)[75], electronic nose technology coupled
with GC/MS [35,60], nanotechnology based artificial nose (NA-
NOSE) in combination with GC/MS [29], in addition to our
solvent sample extraction-GC/MS method. The methods of VOC
identification when performed have been variable as well.
Our study demonstrates the importance of analysis method and
database selection for purposes of compound identification. The
Agilent Enhanced Chemstation MSD Data Analysis Tool/NIST
W8N08 search emphasized identification of unique chromato-
graphic features, whereas the XCMS Online/METLIN search
focused upon identification of feature differences between groups,
with emphasis on minor peaks within chromatograms. Standard
chemical databases such as NIST W8N08 contain many classes of
compounds including industrial solvents, toxicants, and biohaz-
ardous materials. Metabolomic database searches appear more
likely sources for identification of compounds produced by living
organisms or cell-based structures; however, the number of
compounds and species represented in metabolomics databases
are often limited [49,77]. Utilizing a combined chemometric-
bioinformatics approach may provide the best method for
identification of unique or dysregulated peaks within chromato-
grams until such time that metabolomic databases are capable of
functioning as standalone references.
The potential influence of endogenous and exogenous VOCs,
the variability in collection strategy, analysis methodology, and
VOC identification underscores the difficulty of identification of
VOCs as biomarkers for specific pathogens or diseases, and the
need for cross-validation and standardization of breath analysis
methods. It will be especially important to consider the potential
confounding influences of endogenous and exogenous VOC
sources when performing breath analysis on animals under field
conditions. In principle, breath analysis could be applicable to all
animal species, although modification of systems used in human
breath analysis is required. In many animal species sample
collection is not voluntary and collection of an alveolar breath
sample is not possible. This necessitates capture of breath samples
via mask or nasal collection systems [61], and expectations that
samples will likely contain VOCs derived from the upper
respiratory or gastrointestinal tracts.
The strengths of this study include the ability to control for
many endogenous and exogenous factors that might affect breath
VOC profiles. The test subjects were all male Holstein calves of
the same approximate age housed under the controlled environ-
mental and dietary conditions. Inoculum preparation and the
nebulization method used were consistent. Sample collection was
conducted over the same time period on consecutive days, and
sample handling was consistent across all treatment groups.
Limitations of this study include the low number of study animals,
immunological evidence of prior exposure to NTM in some of the
test subjects, and lack of comparative breath analysis research in
healthy cattle, tuberculous cattle, or cattle infected with BRD or
other etiological agents.
Continued investigation and refinement of our breath collection
system and our methods may lead to development of diagnostic
strategies and disease surveillance monitoring systems that could
preclude individual animal handling. Advantages to such systems
would include decreased stress on individual animals, decreased
cost and labor, ability to screen groups of animals, and potential
surveillance of wildlife reservoirs of zoonoses and diseases of
agricultural importance. Future work should include continued
research using experimentally infected cattle and naturally infected
cattle, multiple time point sample collections, collection of biofluid
and tissue samples, increased sample sizes, comparative studies
examining the VOC profiles produced by cattle with other
infectious diseases and by cattle housed in different environments
and fed different diets, and compound confirmation using
reference standards. The eventual transfer of developed laboratory
methods to portable GC-MS or Electric Nose systems would be
beneficial and future work will ideally incorporate such tools.
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